A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	B-cell neoplasm, B-cell non-Hodgkin lymphoma, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, bone marrow disorder, cardiovascular disorder, hematologic disorder, hemorrhagic disease, histiocytic and dendritic cell neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, mycosis fungoides, myelodysplastic syndrome, myeloid leukemia, neoplasm, plasma cell neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-06-10		NCT03017820

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Mayo Clinic	970
National Cancer Institute (NCI)	3015

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Mayo Clinic in Arizona	Scottsdale	United States	191
Mayo Clinic in Rochester	Rochester	United States	687